Not only does it increase the risk of developing HLH/HLH-like systemic illnesses in patients with SPTCL, but the high prevalence of HAVCR2 mutations in our pediatric SPTCL population suggests that it can also accelerate the development of the disease at a young age. This evidence concerns the gene HAVCR2 and hemophagocytic syndrome.